Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; Department of Public Health Sciences, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
J Geriatr Oncol. 2023 Nov;14(8):101650. doi: 10.1016/j.jgo.2023.101650. Epub 2023 Oct 26.
Older adults with cancer have unique fall risk factors related to their disease and treatment such as polypharmacy and neurotoxic treatments. In this secondary analysis, we identified modifiable risk factors associated with future falls among older adults with advanced cancers.
Data were from the COACH study (ClinicalTrials.gov: NCT02107443; PI: Mohile). Patients were age ≥ 70, had stage III/IV solid tumor or lymphoma, ≥1 geriatric assessment impairment, and were receiving palliative intent treatment. Falls were self-reported at baseline (in the past six months), four to six weeks, three months, and six months. We generated inverse probability weights to account for mortality-related loss to follow-up and applied these in generalized linear mixed models to estimate incidence rate ratios.
Of 541 patients (mean age: 77, standard deviation [SD]: 5.27), 140 (26%) reported prior falls at baseline, and 467 (86%) had falls data for ≥1 follow-up timepoint. Of those, 103 (22%) reported at least one fall during the follow-up period, and 112 (24%) had incomplete follow-up due to death. In fully adjusted models, prior falls and impaired Timed Up and Go score were associated with higher incidence of falls over 6 months.
We identified several potentially modifiable fall risk factors in older adults with advanced cancers. Future studies should consider ways to integrate fall risk assessment into ongoing cancer care and intervene to reduce falls in this population.
患有癌症的老年人存在与疾病和治疗相关的独特跌倒风险因素,例如多种药物治疗和神经毒性治疗。在这项二次分析中,我们确定了与晚期癌症老年患者未来跌倒相关的可改变风险因素。
数据来自 COACH 研究(ClinicalTrials.gov:NCT02107443;PI:Mohile)。患者年龄≥70 岁,患有 III/IV 期实体瘤或淋巴瘤,存在≥1 项老年综合评估受损,并且正在接受姑息性治疗。跌倒情况是在基线(过去六个月内)、4 至 6 周、3 个月和 6 个月时进行自我报告的。我们生成了逆概率权重来解决与死亡率相关的随访失访问题,并将这些权重应用于广义线性混合模型中,以估计发病率比。
在 541 名患者(平均年龄:77 岁,标准差 [SD]:5.27)中,有 140 名(26%)患者在基线时报告了先前的跌倒,有 467 名(86%)患者有≥1 次随访时间点的跌倒数据。其中,有 103 名(22%)患者在随访期间报告了至少一次跌倒,有 112 名(24%)患者因死亡而导致随访不完整。在完全调整的模型中,先前的跌倒和计时起立行走测试评分受损与 6 个月内更高的跌倒发生率相关。
我们在晚期癌症老年患者中确定了几个潜在的可改变的跌倒风险因素。未来的研究应考虑将跌倒风险评估纳入现有的癌症护理中,并采取措施减少该人群的跌倒。